Pamidronate disodium /30 mg
Products billed under this code include Pamidronate Disodium.
Payment limit per 30 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Pamidronate Disodium.
Payment limit per 30 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Pamidronate Disodium | Pfizer Inc | 61703-0324-18 | 1 | $11.306 |
| Pamidronate Disodium | Pfizer Inc | 61703-0325-18 | 2 | $22.612 |
| Pamidronate Disodium | Pfizer Inc | 61703-0326-18 | 3 | $33.918 |
| Pamidronate Disodium | Mylan Institutional LLC | 67457-0430-10 | 1 | $11.306 |
| Pamidronate Disodium | Mylan Institutional LLC | 67457-0446-10 | 3 | $33.918 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $11.306 | −$0.719 | 30 MG | Pamidronate disodium /30 mg | v1, posted September 17, 2026 |
| 3Q26 | $12.025 | −$0.399 | 30 MG | Pamidronate disodium /30 mg | v1, posted September 15, 2026 |
| 2Q26 | $12.424 | +$1.134 | 30 MG | Pamidronate disodium /30 mg | v1, posted September 15, 2026 |
| 1Q26 | $11.29 | +$1.647 | 30 MG | Pamidronate disodium /30 mg | v1, posted September 15, 2026 |
| 4Q25 | $9.643 | −$1.517 | 30 MG | Pamidronate disodium /30 mg | v1, posted September 8, 2026 |
| 3Q25 | $11.16 | −$2.716 | 30 MG | Pamidronate disodium /30 mg | v1, posted March 10, 2026 |
| 2Q25 | $13.876 | +$1.293 | 30 MG | Pamidronate disodium /30 mg | v1, posted March 10, 2026 |
| 1Q25 | $12.583 | −$0.031 | 30 MG | Pamidronate disodium /30 mg | v1, posted December 19, 2025 |
| 4Q24 | $12.614 | +$0.947 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 11, 2025 |
| 3Q24 | $11.667 | −$2.43 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 11, 2025 |
| 2Q24 | $14.097 | +$5.223 | 30 MG | Pamidronate disodium /30 mg | v1, posted March 11, 2025 |
| 1Q24 | $8.874 | −$1.458 | 30 MG | Pamidronate disodium /30 mg | v1, posted December 19, 2024 |
| 4Q23 | $10.332 | +$0.016 | 30 MG | Pamidronate disodium /30 mg | v1, posted October 10, 2024 |
| 3Q23 | $10.316 | −$0.254 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 5, 2024 |
| 2Q23 | $10.57 | +$0.19 | 30 MG | Pamidronate disodium /30 mg | v1, posted February 23, 2024 |
| 1Q23 | $10.38 | −$0.601 | 30 MG | Pamidronate disodium /30 mg | v1, posted December 6, 2023 |
| 4Q22 | $10.981 | +$0.405 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 22, 2023 |
| 3Q22 | $10.576 | +$0.425 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 9, 2023 |
| 2Q22 | $10.151 | −$0.403 | 30 MG | Pamidronate disodium /30 mg | v1, posted December 14, 2022 |
| 1Q22 | $10.554 | +$1.396 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 8, 2022 |
| 4Q21 | $9.158 | +$0.846 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 2, 2022 |
| 3Q21 | $8.312 | −$1.834 | 30 MG | Pamidronate disodium /30 mg | v1, posted June 2, 2022 |
| 2Q21 | $10.146 | −$0.558 | 30 MG | Pamidronate disodium /30 mg | v1, posted March 1, 2022 |
| 1Q21 | $10.704 | – | 30 MG | Pamidronate disodium /30 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.